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G row th horm one (GH) is responsible for diverse physiological 
processes. In order to carry out these processes, it uses several signaling 
pathways involving dimerization of GHRs, formation of GHR-JAK2 com plex, 
and activation of the com plex by phosphorylation. One of the pathways it 
uses is PKC signaling pathway. There is evidence indicating PLC-gam m al is 




Growth horm one (GH), an anabolic horm one, has been linked to  
diverse physiological processes. Major roles in which GH is known for are its 
involvem ent in body grow th and muscle development. Also, GH has been 
found to play a role in metabolic functions such as lipid oxidation, amino add  
uptake, and protein sythesis (Argesinger & Carter-Su, 1996). Due to GH 
diverse roles, it was suspected that GH uses a number of signaling pathways. 
One of the GH signaling pathw ays for w hich evidence is starting to 
accumulate is PLC-gamma. In this paper, structures and functions of GH and 
its receptor GHR will be reviewed. Also, signaling pathways involving JAK2 
will be addressed. Furthermore, the background information of PLC and its 
possible involvement in GH signaling pathway will be considered.
Growth Hormone
Background information regarding grow th hormone:
Growth horm one (GH) is made up of a family of proteins and is 
heterogenic (Beattie & Flint, 1993). A ccording to Beattie and Flint (1993), 
heterogeneity may occur at genomic level, causing varitaions in terms of size, 
glycosylation, phosphorylation, and acetylation. Although sizes of GH vary, 
22 kDa is considered the common form. Also, GH has been found to form a 4- 
alpha helix (Beattie & Flint, 1993). GH is released from the pituitary gland into  
circulation, to be detected by target organs. One of the main target organs for 
GH is the liver. In order for GH to take its effects, it must bind to receptors on 




Two types of receptors in cell plasm a membrane has been found to 
bind to human grow th horm one (hGH): grow th hormone receptor (GHR) 
and prolactin receptors. In this paper, we will focus mainly on GHR. GHRs 
have been show n to be a m ember of cytokine/hem atopoietin receptor 
superfam ily (Bazan, 1990). This superfam ily also includes prolactin , 
erythropoietin and some grow th-factor related receptors (Campbell, 1997). 
One characteristic feature of this family is that they are able to produce a wide 
varitey of effects on a large numbers of tissues and cells (Argetsinger & Carter- 
Su, 1996).
GHRs are made up of 620 amino adds. Also, GHRs are glycoslyated and 
ubiquitin-conjugated, although their functions are still unknown (Beattie & 
Flint, 1993). GHRs, which are single-pass receptors, generally have three parts: 
extracellular protein domain, a transmembrane domain, and an intracellular 
domain (Argetsinger & Carter-Su, 1996; Kossiakoff, 1995).
The extracellular domain of GHR, which is also known as grow th  
hormone binding protein (GHBP), consists of 28 kDa of proteins or 246 amino 
adds. It contains ligand-binding portion WXSWS (deVos et al., 1992) . In 
humans, extracellular domain includes two domains which are each made 
up of antiparallel seven beta strands (Kossiakoff, 1995; Postel-Vinay & 
Findori, 1995). The N-term inal portion of the domain consists of six cysteine 
residues, which join together to form three disulfide bonds (Postel-Vinay & 
Findori, 1995). It is suspected that GHBP m ight be involved in horm one 
clearance regulation (Kossiakoff, 1995; VanderKuur et al. 1994). Also, GHBP 
on its own has been identified as a soluble variant of GHR (Beattie & Flint, 
1993; Postel-Vinay & Findori, 1995). This variant has been found in blood
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serum and biological fluids (Baumann et al. 1986; Postel-Vinay et al. 1991). It 
is believed that this variant GHBP is derived from proteolytic cleavage of the 
full-length membrane receptor (Leung et al. 1987; Postel-Vinay & Findori, 
1995).
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Figure 1. Schematic depiction of GHR and GHBP. (Postel-Vinay &
Finidori, 1996)
Transmembrane portion of the receptor consists of 24 amino add. Little 
information was available on significance or specific function of this portion. 
It is believed that transmembrane is a passive component of signaling process 
(Penta & Carpenter, 1997).
Intracellular domain of the receptor plays a crurial role in cellular 
signal transduction (e.g. Argetsinger & Carter-Su, 1996; Bauman et al, 1994). It 
contains of two motifs: Box 1 and Box 2. Box 1 is proline-rich and it is found 
doser to the membrane. It cosists of eight amino adds (hydrophobic residues- 
X-X-X-A l-P-X-P) (Bazan, 1989; Carter-Su et al., 1996; Cosman et al, 1990). In 
mammals, the sequece is ILPPVPVP. Box 1 is commonly found in
cytokeine/hem atopoietin superfamily. Box 2 consists of hydrophobic amino 
adds and charged amino adds. Box 2 is found approximately 30 amino adds 
carboxy terminal to Box 1 (Carter-Su et al., 1996).
Binding of GH and receptor dimerization;
M any studies have reported that intial stage of GH signaling is 
characterized by binding of GH to two GHRs (Argetsigner & Carter-Su, 1996). 
It has been found that GH contains two receptor sites, site 1 and site, 2 which 
allow them to bind to two receptors (Smit & Carter-Su, 1996). It was observed 
that hydrophobic portion of GHR, which is located on the inside, is m ore 
critical in binding (W ells, 1996). Reaction which followed between the two 
receptor molecules account for the formation of homodimer complex (de Vos 
et al., 1992). It appears that GH-GHR binding occurs sequentially with site 1 
binding to receptor prior to site 2 binding (Wells, 1996). It has been reported  
that disturbance in one of the binding sites causes cessation of GH action (Fuh 
et al., 1992).
Also, in binding, extarcellular domain of receptors can accom adate for 
a cavity in Site 1 of GH (Kossiakoff, 1995). It has been proposed that 
dimerization of GHR and associated conformational changes are necessary for 
GH action (Carter-Su et al., 1996) and for cellular proliferation (Argetsinger & 
Carter-Su, 1996).
JAK2 tyrosine kinase activation by GH:
GHR dimerization is rapidly followed by binding of JAK2 to GHR and 
its activation. JAK2, which is a member of Janus family, is a tyrosine kinase. 
At present, Janus family includes JAK1, JAK2, JAK3 and tyk2 (Argetsinger &
Carter-Su, 1996; Firmbach-Kraft et al., 1990; H arpur et al., 1992). It has been 
observed that even though JAK2 is the most crucial one to be activated by 
GHR dimerization, JAK1 and JAK3 may also play a lesser role in moderating 
GH effects (Argetsinger & Carter-Su, 1996; Carter-Su, 1996).
Furtherm ore, the significances of JAK kinases are not limited to GH. 
JAK kinases are activated by m ost members of cytokine/hem atopoeitin  
receptor family members with differential preferences (Argetsinger & Carter- 
Su, 1996; Carter-Su et al, 1996). Variations in activation preferences and 
ch aracteristics account for signaling specificity seen am ong receptors 
(Argetsinger & Carter-Su, 1996).
This specificity seen am ong signaling receptors is a crucial link in 
understanding GH signaling. Following form ation of GHR-GHR com plex, 
JAK2 affinity for GHR increases (Argetsinger et al., 1993; Argetsinger & Carter- 
Su, 1996). Studies have also shown that mutation in Box 1 of GHR leads to 
disruptions in GH action (Argetsinger & Carter-Su, 1996). M oreover, Box 1 
appears to be essetial for GHR-JAK2 com plex form ation and for eventual 
tyrosyl phosphorylation of JAK2 (Argetsinger & Carter-Su, 1996; Frank et al., 
1994). Thus, Argetsinger & Carter-Su (1996) had suggested that JAK2 binds 
directly to Box 1 of GHR. This binding of two JAK2 molecules to two receptors 
lead to tyrosyl phosphorylation of kinase domain of the JAK2 m olecules 
(Argetsinger & Carter-Su, 1996). This activates JAK2.
Immediately following JAK2 activation, cytoplasm ic domain of GHR 
appears to be phosphorylated by JAK2 (A rgetsinger et al, 1993). It was 
suggested that depending on the type of tyrosine phosphorylated on JAK2, 
JAK2 is able to signal multiple signaling pathways. This suggestion is
supported byt the findings of a number of tyrosines in JAK2 (e.g. 48 tyrosines 
in murine JAK2) (Argetsinger & Carter-Su, 1996).
Therefore, in sum m ary, form ation of GHR dim erization makes it 
possible for two JAK2 molecules to bind with two GHRs. This in turn causes 
tyrosyl phosphorylation of kinase dom ain of JAK2, leading to JAK2 
activation. It has been proposed that the crucial role of GHR dim erization is 
to activate JAK2 and in later signaling events, JAK2 m ay be m ore essential 
than GHR (Carter-Su et al., 1996).
The role of SH2 in GH signaling:
Tyrosyl phosphorylation has been associated w ith binding of Src 
homology 2 (SH2) of specific proteins to JAK2. This binding appears to have 
modulatory effects on signaling processes (Pawson & Schlessinger, 1994). It is 
believed that these proteins are also phosphorylated by JAK2 (Carter-Su et al., 
1996). Also, the ability to bind to SH2 of specific proteins implicates that there 
exits specific signaling pathways (Pawson & Schlessinger, 1993). These specific 
signaling pathways are believed to involve tyrosine kinases and phosphatases 
(Carter-Su et al., 1996). Some of the signaling pathw ays that have been  
obsesrved are m itogen-activated protein (MAP) kinases, insulin receptor 
substrates 1 and 2, phosphatidylinositol 3' kinase, and protein kinase C (PKC). 
Here, a brief overview of these pathways will be given.
Involvement of GH in MAP kinases signaling pathway:
MAP kinases, which are im portant for regulation of grow th and 
differentiation, necessitate phosphorylation by tyrosine and threonine to be 
activated (Argetsinger & Carter-Su, 1996; Cobb & Goldsmith, 1995). They have
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been found to be activated by GH and a num ber of tyrosine kinases 
(Anderson, 1992; Carter-Su et al., 1996; Campbell et al., 1992). Two types of 
MAP kinases that were found to be activated by GH are ERK1 and ERK 2.
One of the pathways in which GH activates M AP kinases involves 
SHC, Grb2, son-of-sevenless (Sos), ras, raf, and MEK (Crews & Erickson, 1993). 
One experiment using 3T3-F442A fibroblasts has shown that GH is involved  
in tyrosyl phosphorylation of the 46-, 52-, and 66- kDa SHC proteins (Carter- 
Su et al., 1996). This result and other experimental evidences indicate that GH 
prom otes association of SH2 dom ain of SHC proteins w ith JAK2-GHR 
complexes (Argetsinger & Carter-Su, 1996; Carter-Su et al., 1996). It is assumed 
that JAK2 phosphorylates SHC after binding (Argetsinger & Carter-Su, 1996). 
Phosphorylation of SHC makes attachm ent of Grb2 possible (Argetsinger & 
Carter-Su, 1996). Even though detail mechanisms involving the rest of the 
signaling molecules (Sos, ras, raf, and MEK) remain to be uncovered, it is 
suspected that procurement of SHC and Grb2 are inital stages of ERKs 1 and 2
Figure2: Summary of the pathwasys (Carter-Su et al., 1996)
IRS-1, IRS-2, PI 3' Kinases and GH:
It has been observed that if cells are deprived of GH, they start to show 
signs of insulin-like effects (Davidson, 1987). Therefore, it was suspected that 
GH and insulin have some signaling pathways in common (Argetsinger & 
Carter-Su, 1996). However, the mechanism is expected to differ in some ways. 
One way in which GH mechansim may work is by utiliztion of JAK2 as an 
intermediary in assocation with GHR-JAK2 com plex (Argetsinger & Carter- 
Su, 1996). IRS-1 and ERS-2 are thought to be the substrates involved (W hite, 
1996). This interaction provides binding site for PI 3’ kinase (Argetsinger et al., 
1995, Argetsinger & Carter-Su, 1996). It is believed that PI 3' kinase promotes 
insulin-like effects of GH.
STATs and GH:
It has been observed that GH can have im pacts at genom ic level, 
regarding growth and metabolism (Smit et al., 1996). One way of achieving 
this is by activating Stat (signal transducers and activators of transcription) 
proteins. Stat family of proteins have been recognized as gene transcription  
factors. Stat 1, Stat 3, and Stat 5 appears to be significant factors in gene 
regulation while Stat 4 appears to play a lesser role. Depending on the type of 
cell, one of these four Stat proteins will be activated (Argetsinger & Carter-Su, 
1996).
Studies have shown that activation of Stat by GH requires JAK2 (Han et 
al, 1996). It appears that JAK2 activation causes recruitm ent of specific Stat 
proteins (Smit et al., 1996). After binding of SHC domain of Stat protein to 
GH R-JAK2 com plex, S tat is p h osp h orylated  by JA K 2. Follow ing  
phosphorylation, Stat protein associates with other Stat proteins to form
hom odim ers and heterdim ers. They then detached from  GHR-JAK2 
complex. A t this time, Stat protein can translocate to the nucleus, to govern  
transcriptional processes of specific genes (Smit et al., 1996).
PKC and GH:
Protein kinase C (PKC) is a member of serine /  threonine kinase family, 
which has been a known protein phosphorylater and activator. The roles for 
which PKCs have been associated are cellular grow th, m etabolism  and 
differentiation (Argetsinger & Carter-Su, 1996; Dekker & Parker, 1994; Hug & 
Sarre, 1993) So far, 12 PKC isoforms has been identified.
Also, studies have shown that some of GH regulated processes such as 
lipogenesis can be inhibited by reduction in PKC (Argetsinger & Carter-Su, 
1996; Gronowski et al., 1995). Therefore, it was suspected that GH m ay 
m oderate these some processes by PKC activation (Argetsigner & Carter-Su, 
1996). Perhaps due to existence of isoforms, a number of signaling pathways 
have been seen in GH activation of PKC. Some of the possible prom oters of 
PKC activation are IRS-1, IRS-2, PI 3' kinase, phospholipase D and  
phosphatidylcholine (Argetsinger & Carter-Su, 1996; Carter-Su et al., 1996). 
Here, however, we will focus on possible involvement of PLC-gamma, which 
has only recently became a candidate for PKC activation promoter.
Phospholipase C
Before considering PLC-gamma specifically, we will briefly discuss its 
broader category, phospolipase C. It has been found that activation of 
phospholipase C can be achieved via phosphorylation of tyrosine kinases by 




phospholipase C (PLC) is to produce sencond m essengers, diacylglycerol 
(DAG) and Ins 1, 4, 5-P3 (IPs), by hydrolyzing PI 4,5 P2. Release of DAG 
activates the PKC pathway while IP3 acts on membrane of endoplasmic 
reticulum to release Ca 2+ (Kamat & Carpenter, 1997). Since PLC substrate is 
located in membrane, PLC m ust interact with membrane during substrate- 
enzyme reaction (Singer et aL, 1997).
Figure 3: Summary of PLC reaction (Singer et al., 1997)
Currently, ten isozymes of PLC have been recognized and they have  
been categorized into three types: PLC-beta, PLC-gamma and PLC-delta. They 
are all polypeptides (Rhee & Bae, 1997). Structurally, all PLC isoforms contain 
X and Y regions, which are considered catatlytic core of the PLC molecule (Ji et 
al., 1997; Singer et al., 1997). X region contains approxim ately 170 residues 
while Y region contains approxim ately 260 residues. These X and Y regions 
tightly bind together to form  a strucutre known as TIM barrel structure 
which has an active site at C-terminus (Kamat & Carpenter, 1997). In PLC- 
gamma forms, X and Y regions are separated by approxim ately 400 amino 
adds (Rhee & Bae, 1997).
In addition to X and Y  regions, m ost PLC isozym es include a N- 
terminal pleckstrin homolgy (PH) domain, and a C2 homology domain
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(Singer et al., 1997). Although exact role of PH is unclear, it has been seen in 
association with PIP2. The C2 domain, on the other hand, is necessary for Ca2f 
of the enzyme (Singer et al., 1997). PLC-delta isoform, which weighs 85 kDa, is 
seen as the most basic form of PLC while PLC-beta and PLC-gamma contain 
additional structures to promote regulatory properties (Singer et al., 1997). It is 
suggested that PLC-beta and PLC-gamma arose from PLC-delta (Rhee & Bae, 
1997). PLC-beta weighs approximately 150 kDa and is made up of four genes 
(Kamat & Carpenter, 1997). It is suspected that activity of PLC-beta is regulated 





1/2 N- c- 1/2
X PH SH2 SH2 SH3 PH
Cal B
Y7S3 V759
Gamma 2 N ---
1/2 N- u- 1/2
PH SH2 SH2 SH3 PH Cal B
Delta N ■
PH EF Cal B
• — 1;----- r*—:■« 1 : ^ -  -  j ____
Figure 4: Types of PLCs (Kamat & Carpenter, 1997)
PLC-Gamma:
The most distinguishing feautre of PLC-gamma is that it contains two 
SH2 regions (N-SH2 and C-SH2) and one SH3 region. Although it is a notable 
feature for a PLC, it is com monly seen in signaling pathw ays involving 
tyrosine kinases (Cohen et al., 1995; Kamat & Carpenter, 1997; Pawson, 1995). 
These regions may not be crucial in PLC-gam m al catalytic activity but they 
may have modulatory effects (Penta & Carpenter, 1997).
So far, two types of PLC-gamma have been identified: PLC-gam mal and 
PLC-gam m a2. Genes for PLC -gam m al and PLC-gam m a2 are found on 
chrom osom es 20 and 16 in humans, and chrom osom es 2 and 8 in m ice 
(Argeson et al., 1995; Hernandez et al., 1994; Kamat & Carpenter, 1997; Nelson 
et al., 1992). They weigh approximately 145 kDa. Out of the two form s, PLC- 
gam m al has larger range of target areas while effects of PLC-gam ma2 are 
limited to spleen and thymus (Emori et al., 1989). It is believed that PLC- 
gam m al plays an intermediary role in GH-dependent PKC signalling pathway 
and is responsible for control of intracellular Ca 2+ level.
One structural feature that allows PLC-gam m al to play its roles is SH 
region in betw een X and Y regions (K am at & C arpenter, 1997). A fter 
formation of GH-induced GHR-JAK2 complex, this SH2 region is needed to 
interact with binding sites located on the receptors (Penta & Carpenter, 1997; 
Singer et al., 1997). It has been proposed that this high affinity binding may 
lead to conform ational changes and eventually result in phosphorylation  
(Penta & Carpenter, 1997).
One conformational change that has been suggested is that SH region 
would create a extended loop, starting from the X and Y regions (Kamat & 
Carpenter, 1997). In this model, there are two phosphorylation sites in this
loop: site Tyr 771 and site Tyr 783. There is also one more site, T yrl254, which 
is further rem oved from the loop. Tyr 783 is the m ost critical site during 
phosphorylation while the other two sites serve to ensure maximum activity 
(Kamat & Carpenter, 1997). Some studies have shown that Tyr 771 is not 
necessary (Kim et al., 1991). During phosphorylation, SH2 regions can be seen 
playing a modulatory role.
Two changes have been observed during this phosphorylation period. 
One is that there is a difference in Ks and Km (Wahl et al., 1992). Another 
change that has been seen is an increaesd in H2Q2 level, which may serve as 
intracellular messenger (Bae et al., 1997; Rhee & Bae, 1997).
A fter phosphorylation, PLC -gam m al is activated  and it rapidly 
detaches from the complex to attaches itself to plasma membrane (Kamat & 
Carpenter, 1997). This activation now enables PLC-gam mal to hydrolyze DAG 
and PIP2, (Liao et al, 1993). It is also suggested that some parts of membrane, 
such as phosphatidic add and PIP3, may also contribute to activation (Kamat 
& Carpenter, 1997). This activation mechanism can be seen in platelet-derived 
growth factor, epidermal growth factor, fibroblast grow th factor, nerve growth 
factor, and hepatocyte growth factor (Rhee & Bae, 1997).
Additionally, there are ways of inhibiting this activation process. One is 
to remove agonist, which will lead to dephosphorylation and deactivation of 
PLC-gam m a (Kam at & Carpenter, 1997). Also, it is suspected that PLC- 
gam m al has an intracellular inhibitory m echanism  within the SH region  
(Kam at & Carpenter, 1997). Exact region and enzym es involved in this 
inhibition process is not well-understood. However, abnormal lack of PLC- 
gam m al activity has significant physiological application. In mammalian 
PLC-gam mal (-/ -) embryo, development and growth fail to occur, leading to
death of the embryo (Ji et al., 1997; Kam at & C arpetner, 1997). This 
phenomenon is not seen in PLC-gam m al (+ /-) or (+ /+ ). Therefore, PLC- 
gam m al is significant contributor in GH signaling processes.
Conclusion
In summary, GH is responsible for grow th and development of bones 
and muscles. To do this, GH uses signaling process involving GHR and 
tyrosine kinase JAK2. Phosphorylation of GHR-JAK2 leads to opening up of 
docking sites, which allow SH2 of specific proteins to bind. This scenario can 
be applied to pathway using PLC-gam m al. Activation of PLC-gam m al leads 
to hydrolyzation of DAG and IP3. Activation of DAG leads to activation of 
PKC pathway while activation of IP3 leads to increase intracellular Ca 2+. Both 
of these factors are contributors of GH regulatory mechansim.
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